Natco Pharma stock awaits results and dividend decision Friday

Natco Pharma's board is scheduled to meet on Friday, November 13, 2026, to consider unaudited results for the quarter ended September 30 and a possible second interim dividend, according to The Economic Times. The decision puts the company's September-quarter performance and capital-allocation policy in focus for investors.

Results decision due Friday

The meeting notice covers unaudited financial results for the period ended September 30, 2026. It also includes a potential second interim dividend, so the board outcome may provide the next clear signal on earnings and shareholder distributions.

Natco Pharma's latest investor-relations materials list consolidated revenue of INR 794.4 crore and profit after tax of INR 206.5 crore for the first quarter of fiscal 2027. Those figures provide the most recent company-reported operating reference ahead of the September-quarter review.

Rights issue changes capital base

The company completed a rights issue in October. The transaction involved 17,058,082 shares, with the allotment approved on October 23, 2026, according to the announcement record carried by The Economic Times. The larger equity base is relevant when investors assess per-share earnings and any dividend decision.

NATCO Pharma stock was quoted at 808.80 Indian rupees on the National Stock Exchange at 3:30 p.m. IST on Thursday, November 12, 2026. The market quote is presented without a daily direction because no compatible Xetra comparison is available.

India's broader market setting is covered by the BSE Sensex.

More news and analyses on Natco Pharma stock.